June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Retinal biomarkers for potential diagnosis of late stage of Alzheimer’s Disease
Author Affiliations & Notes
  • David Abram
    Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, United States
  • Than Sein
    Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, United States
  • Vladimir Bondarenko
    Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, United States
  • Footnotes
    Commercial Relationships   David Abram None; Than Sein None; Vladimir Bondarenko None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3885 – A0087. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Abram, Than Sein, Vladimir Bondarenko; Retinal biomarkers for potential diagnosis of late stage of Alzheimer’s Disease. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3885 – A0087.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Alzheimer’s Disease (AD) is a common neurological disorder affecting millions of individuals worldwide. We performed an experimental model and attempted to identify retinal biomarkers that can be used for a noninvasive diagnosis of this brain disorder.

Methods : Cryosections of brains and retinas from cadavers were analyzed. 2 cadavers without a history of neurodegenerative disease (1 male, 1 female) and 4 cadavers affected by AD (2 males, 2 females) were used. The structures of the brain specifically focused on were the prefrontal cortex (PFC), hippocampus, temporal lobe, visual cortex. Each tissue section was immunostained with antibodies against total tau (TT), phospho-tau 181 (PT181), phospho-tau 205 (PT205), and beta-amyloid (BA). Every stained section was then microscopically analyzed to compare and contrast each marker using optical density (OD) measurements.

Results : Retina samples of AD cadavers expressed a statistical significance increase in OD of the TT marker when compared to normal cadavers (AD = 0.37 OD ± 0.179, Normal = 0.01 OD ± 0.0049). In regards to the brain structures, only the TT markers in PFC were found to have statistical significant increases in OD value (AD = 0.28 OD ± 0.0621, Normal = 0.04 OD ± 0.0423). TT, PT181, PT205, and BA also expressed slight increases in OD in several brain structures of the AD cadavers but were not found to be statistically significant.

Conclusions : There is a significant increase in the TT marker in the retina with similar findings in the PFC. This suggests that using TT as a marker in the PFC and retina has the highest potential to aid in diagnosing AD, with a possibility of studying the progression of AD through TT in different areas of the brain in future research.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×